Safety and Efficacy of Salsalate to Treat Endothelial Dysfunction in HIV-infected Adults
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This is a phase II, open label, randomized-controlled pilot study designed to study both the
efficacy and safety of salsalate in decreasing endothelial cell dysfunction, systemic
inflammation, and insulin resistance in HIV-infected adults. The investigators hypothesis is
that salsalate will reduce inflammation and therefore endothelial cell activation and insulin
resistance. The sample size will be 40, with an equal number of people being randomized to
one of two groups. The first arm will be randomized to salsalate therapy. The second arm will
act as a control group. The study duration will be 13 weeks.